Biopsy-Proven Nonalcoholic Fatty Liver Disease

WASHINGTON — The term ‘non-alcoholic fatty liver disease’ no longer reflects current knowledge of the disease and should be changed, members of the NAFLD Nomenclature steering committee noted during The Liver Meeting.

WASHINGTON — Adding weight management care into a multidisciplinary nonalcoholic fatty liver disease program improved referrals for bariatric surgery at a rate of 25 times higher than the national average, according to Yale study results.

Healio handpicked its top stories on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, which highlight risks for children with NAFLD, how fatigue relates to quality of life, treatment with resmetirom and more.

LONDON — Longitudinal serum alanine aminotransferase trajectories remained stable over time among a subset of patients with nonalcoholic fatty liver disease, according to research presented at the International Liver Congress.

LONDON — Ozempic improved cardiometabolic parameters and markers of liver injury yet failed to improve liver fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis, according to late-breaker data presented here.

LONDON — Magnetic resonance elastography in combination with the fibrosis-4 index was a better predictor of significant fibrosis in patients with nonalcoholic fatty liver disease vs. other noninvasive techniques, noted a presenter here.

LONDON — Nonalcoholic fatty liver disease and alcohol-associated liver disease are among the main contributors of increased mortality related to chronic liver disease and liver cancer burden, according to research.

Patients with non-alcoholic fatty liver disease benefited from encouragement to complete a low-energy diet even if there were no adherence issues with intervention plans, according to results published in BMJ Open Gastroenterology.

Among patients with nonalcoholic fatty liver disease and advanced fibrosis, food insecurity significantly correlated with greater all-cause mortality, according to a presenter at the International Liver Congress.

A novel GaINAc-conjugated RNAi therapeutic meant to replicate the protective nature of a mutation showed promising efficacy in a proof-of-concept study in the first five patients treated with the medication.